Rose K M, Stetler D A, Jacob S T
Proc Natl Acad Sci U S A. 1981 May;78(5):2833-7. doi: 10.1073/pnas.78.5.2833.
RNA polymerase I was purified to homogeneity from Morris hepatoma 3924A. Purified RNA polymerase I contained a protein kinase activity but comigrated with the polymerase in nondenaturing gels. RNA polymerase II, purified from the same hepatoma, lacked protein kinase activity. Analysis of the subunit composition of the RNA polymerase I showed the presence of eight polypeptides: S1, Mr 190,000; S2, Mr 120,000; S3, Mr 62,000; S4, Mr 42,000; S5, Mr 24,600; S6, Mr 21,000; S7, Mr 19,500; and S8, Mr 17,500. Antibodies prepared against purified polymerase I specifically inhibited RNA synthesis catalyzed by RNA polymerase I. When subunits of the enzyme were covalently linked to diazobenzyloxymethyl paper, complexes between the antibody preparation and S1-S6 were visualized. No immune complexes were formed between RNA polymerase I antibodies and RNA polymerase II subunits. The antibody preparation was able to inhibit both the protein phosphorylation catalyzed by RNA polymerase I and that catalyzed by a nuclear kinase (NII) purified from the same hepatoma. The two polypeptides of the nuclear kinase--Mr 42,000 and 24,600 (identical in size to S4 and S5 of polymerase I)--formed visible complexes with the RNA polymerase I antibodies. Both S4 and S5 of the polymerase contained an ATP binding site, a property associated with protein phosphorylation and also exhibited by the polypeptides of the purified kinase. These data suggest that polypeptides of Mr 42,000 and 24,600 associated with polymerase I are responsible for its kinase activity.
RNA聚合酶I从莫里斯肝癌3924A中纯化至同质。纯化的RNA聚合酶I具有蛋白激酶活性,但在非变性凝胶中与聚合酶迁移率相同。从同一肝癌中纯化的RNA聚合酶II缺乏蛋白激酶活性。对RNA聚合酶I亚基组成的分析表明存在8种多肽:S1,分子量190,000;S2,分子量120,000;S3,分子量62,000;S4,分子量42,000;S5,分子量24,600;S6,分子量21,000;S7,分子量19,500;以及S8,分子量17,500。针对纯化的聚合酶I制备的抗体特异性抑制RNA聚合酶I催化的RNA合成。当该酶的亚基与重氮苄氧基甲基纸共价连接时,可观察到抗体制备物与S1 - S6之间的复合物。RNA聚合酶I抗体与RNA聚合酶II亚基之间未形成免疫复合物。抗体制备物能够抑制RNA聚合酶I催化的蛋白磷酸化以及从同一肝癌中纯化的核激酶(NII)催化的蛋白磷酸化。核激酶的两种多肽——分子量42,000和24,600(与聚合酶I的S4和S5大小相同)——与RNA聚合酶I抗体形成可见复合物。聚合酶的S4和S5均含有ATP结合位点,这一特性与蛋白磷酸化相关,纯化激酶的多肽也具有此特性。这些数据表明与聚合酶I相关的分子量42,000和24,600的多肽负责其激酶活性。